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ABSTRACT  
 
The use of conventional tablets in geriatric patients is currently limited because of a 
decrease in their physiological functions, such as tremor and difficulty of swallowing pills, which 
lowers their compliance with drug therapy. Hypertension, one of the degenerative diseases 
suffered by geriatric patients, is treatable with atenolol tablets or capsules that are less soluble in 
water or, in other words, has a poor dissolution. This research attempted to improve the 
dissolution of atenolol by formulating it into orodispersible tablets (ODTs), and as such, the 
disintegration time was modified by adding co-processed crospovidone-croscarmellose sodium in 
1:1 ratio. Moreover, Poloxamer
®
 188 was added to the formulation of atenolol-β-cyclodextrin 
inclusion complex. The post-compression test revealed that ODTs disintegrated quickly within 
36.67±1.21 seconds (<60 seconds) and had physical characteristics that met the pharmaceutical 
requirements. The amount of atenolol dissolved within 30 minutes in the dissolution study was 
84.39% (%Q30 minutes). The results of the accelerated stability study (at 40 °C and RH 75±5 %) for 
two weeks proved that the physical and chemical characteristics of the produced orodispersible 
atenolol tablets were stable. 
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INTRODUCTION 
The use of conventional tablets today raises problems in geriatric patients, especially who 
receive long-term therapy for degenerative diseases. Patients in this age group show changes in 
their physiological conditions that often lead to tremor, difficulty in chewing and swallowing, and 
proneness to choking (Dashora, 2013). An example of degenerative diseases is hypertension 
(Dipiro, 2008). Atenolol is a hypertension drug that is rather difficult to dissolve in water and has 
low dissolution. Dissolution is a process preceding the absorption of drug substances after which 
the drug can provide the desired pharmacological effect for a particular time (Qiu et al., 2009). 
Dissolution can be improved by modifying the physical features of the drug using specific 
materials to form molecular complexes (Shargel and Yu, 2017). An example of these materials is 
β-cyclodextrin. The outer part of β-cyclodextrin is hydrophilic, while the interior is hydrophobic 
(Vivek et al., 2012; Sinko, 2011).  Previous research has proven how the formation of inclusion 
complexes can increase the dissolution of water-insoluble drugs, such as rosuvastatin. 
Rosuvastatin reacts to the addition of β-cyclodextrin, and in rosuvastatin-β-cyclodextrin inclusion 
complex, the crystallinity of this drug decreases (Akbari et al., 2011). Based on this result, the 
formation of atenolol-β-cyclodextrin inclusion complex is assumed to be able to increase the 
dissolution of atenolol.  
Another strategy to improve the dissolution of atenolol is by formulating orodispersible 
dosage forms. Orodispersible tablets break down or dissolve quickly in the mouth without water 
or chewing. U.S. Food and Drug Administration defines them as tablets that can disintegrate in 
the oral cavity in less than 60 seconds (FDA, 2008). One way to improve the performance of 
superdisintegrants is co-processing, that is, the combination of two ready-made disintegrants with 
the appropriate process. This process is expected to optimize the disintegration of orodispersible 
tablets and produce materials that have better flow properties than simple mixtures of physical 
materials (Ramani et al., 2010). A previous study has found that the co-processing of 
crospovidone and croscarmellose sodium is best when composed in a 1:1 ratio (Mittapalli et al., 
2010). Another study has shown the synergistic use of crospovidone and croscarmellose sodium 
in the formulation of orodispersible ibuprofen tablets at a total concentration of 8-10 %. The 
hardness and disintegration of orodispersible tablets prepared with the combination of these two 
superdisintegrants meet the requirements (Desai et al., 2014). The addition of surfactants in this 
dosage form can also help to reduce surface and interfacial tension and increase particle stability 
(Augsburger and Hoag, 2008). Previous studies indicate that the addition of Poloxamer 188 in the 
tablet matrix increases drug solubility in the matrix and accelerates drug release (Al Hanbali et 
al., 2018).  
In this study, orodispersible atenolol tablets were created by forming atenolol-β-
cyclodextrin inclusion complexes and adding Poloxamer 188, a surfactant, to improve atenolol 
dissolution. The crospovidone-croscarmellose sodium (1:1) was co-processed to accelerate the 
disintegration time of orodispersible tablets and makes the dissolution start faster. These tablets 
were evaluated pre- and post-compression and subjected to an accelerated stability test to 
determine their stability. The parameters observed in the stability test included atenolol levels, 
wetting time, water absorption ration, in vitro dispersion time, and dissolution.  
 
RESEARCH MATERIALS AND METHODS 
Materials 
The materials used in this research were atenolol p.g. (Refarmed Chemicals, Lugano 
Switzerland), β-cyclodextrin p.g. (Roquette, France),  crospovidone (Kollidon® CL) p.g. (BASF 
South East Asia Pte-Ltd), croscarmellose sodium (Ac-Di-Sol) p.g.,  magnesium stearate p.g. (Faci 
Asia Pacific PTE LTD), aspartame f.g. (Ajinomoto CO.INC), Poloxamer 188 (Merck Millipore), 
and methylparaben (Nipagin
TM
). 
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The formulation of atenolol-β-cyclodextrin (1:1) inclusion complexes 
The atenolol-β-cyclodextrin inclusion complex was prepared in a 1:1 molar ratio. β-
cyclodextrin was dissolved in hot water, and atenolol was dissolved in heated ethanol. Then, the 
two solutions were mixed. This mixture was stirred continuously using a stirrer while heated at 
70°C until the solvent evaporated, then the granules were sieved with a 60 mesh and put in the 
oven (Parfati et al., 2017).  
 
The characterization of atenolol- β-cyclodextrin (1:1) inclusion complexes 
The characterization of crystallographic aspects using X-ray diffraction 
The X-ray diffraction patterns of the powder of atenolol-β-cyclodextrin (1:1) inclusion 
complexes were recorded with an x-ray diffractometer (Hitachi) using Cu anodes set at the range 
of 3-80°C (angle 2θ) at room temperature (Gite, 2014). The observation was performed at an 
angle 2θ from 5° to 50°. 
Characterization with infrared spectroscopy (Fourier-transformed infrared) 
 The infrared spectroscopy was used to observe changes in the functional groups of the 
atenolol-β-cyclodextrin (1:1) inclusion complex and compare them to the single component of 
the inclusion complex. The infrared spectra of atenolol, -β-cyclodextrin, and atenolol-β-
cyclodextrin (1:1) were observed in an infrared spectrophotometer (Jasco FT-IR-4200) using the 
KBr pellet method (Ghosh et al., 2011). 
 
Thermal characterization with Differential Scanning Calorimetry (DSC)  
 Thermal characterization was carried out in a Differential Scanning Calorimeter (DSC) 
(Mettler Toledo). The samples of atenolol, β-cyclodextrin, and atenolol-β-cyclodextrin inclusion 
complex weighing ±4 mg were heated at a scanning rate of 10°C/minute from 40°C to 200°C and 
flowed with nitrogen at a rate of 40 ml/minute (Gite, 2014). 
 
Characterization with Scanning Electron Microscopy  
  A small amount of the sample powder (± 5 mg) was prepared on an adhesive attached to the 
aluminum plate. The aluminum plate was then coated with gold under the atmosphere of argon 
gas (Ghosh et al., 2011). The prepared sample was observed under a scanning electron 
microscope (Hitachi SU3500). 
  
The co-processing of superdisintegrants  
 The superdisintegrants were co-processed with the solvent evaporation method. 
Crospovidone and croscarmellose sodium were mixed with a weight ratio of 1:1 and then added 
with ethanol. The mixture was stirred with a magnetic stirrer until the ethanol evaporated. The 
wet granules were sieved with a 60 mesh, then dried in an oven at 60°C. Afterward, the co-
processed superdisintegrants were analyzed with infrared spectroscopy and X-ray diffraction, and 
their moisture content was gauged. 
 
The preparation of orodispersible atenolol tablets 
 The composition of the orodispersible atenolol tablets prepared in this study is presented in 
Table I.  
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Table I The formula of orodispersible atenolol-β-cyclodextrin (1:1) tablets with co-
processed crospovidone-croscarmellose sodium and Poloxamer 188 
Ingredients 
Composition 
% Component 
Amount per tablet 
(mg) 
Atenolol-β-cyclodextrin (1:1) 66.68% 266.73 
Co-processed superdisintegrants. i.e., 
crospovidone-croscarmellose sodium 
(1:1) 
10% 40 
Magnesium stearate 0.5% 2 
Aspartame 2.5% 10 
Mint flavor 1.0% 4 
Aerosil 0.5% 2 
Mannitol DC 3.464% 13.854 
Avicel PH 102 13.856% 55.856 
Talc 1% 4 
Poloxamer 188 0.3% 1.2 
Methylparaben (Nipagin) 0.2% 0.8 
Total 100%     400 
 
After all the ingredients had been weighed, atenolol was first mixed (pre-mixed) with a 
portion of Aerosil in a tumbling mixer for ± 3 minutes and then with some microcrystalline 
cellulose for ± 5 minutes. Aspartame, the remaining microcrystalline cellulose, mannitol DC, and 
mint flavor were added to the tumbling mixer. Afterward, the co-processed superdisintegrants 
(crospovidone and croscarmellose sodium in 1:1 ratio) was added. The ingredients were mixed 
until homogeneous for ± 10 minutes (Parfati et al., 2018). The powder mixture was evaluated pre-
compression to ensure that it was qualified for the next procedure. 
 
Pre-compression evaluation of the powder mixture 
Flow characterization (flow rate and angle of repose) 
 The flow characteristics and angle of repose were determined using the fixed funnel method. 
The powder mixture (± 100 grams) was poured through a funnel placed vertically against a 
horizontal plane at 10.0 ± 0.2 cm high (h). The time that all powder mixture required to empty out 
of the funnel was recorded, and this data was used to calculate the flow rate. The height and the 
base radius of the conical pile of granules on the horizontal plane were measured and used to 
obtain the angle of repose (Aulton and Summers, 2013). 
 
Compressibility Index 
   The bulk density and tapped density of the powder mixture were first measured (Aulton 
and Summers, 2013). The compressibility index of the powder was computed by inputting both 
data to the following equation: 
                       
                    
          
        
Notes: 
ρ (tapped): the tapped density of the powder 
ρ (bulk): the actual (bulk) density of the powder 
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Hausner Ratio 
 The Hausner Ratio is an indirect method for predicting the flow characteristics of the powder 
mixture. Its calculation involved the comparison between the tapped density and the bulk density 
of the powder mixture (Aulton and Summers, 2013). 
Moisture content 
 The moisture content of the powder mixture was gauged with a moisture content analyzer. It 
was calculated using the following equation: 
 
     
    
  
      %.  
Notes: 
MC  : moisture content 
W  : the wet weight of powder mixture 
Wo : the dry weight of powder mixture 
 
The printing of orodispersible atenolol-β-cyclodextrin (1:1) tablets with co-processed 
crospovidone-croscarmellose sodium and Poloxamer 188 
The orodispersible atenolol-β-cyclodextrin tablets were printed by direct compression method. 
Following the pre-compression evaluation, the powder mixture was mixed with an external phase 
(magnesium stearate, talc, and the remaining Aerosil® for 3 minutes were mixed in a tumbling 
mixer until homogeneous). The powder mixture was then compressed into orodispersible tablets 
with Erweka® tablet compression machine (force= 2 tons). The printed tablets weighed 400 mg 
and had a diameter of 11 cm and round, biconvex punch (Parfati et al., 2018).  
Post-compression evaluation 
The post-compression evaluation on the orodispersible atenolol-β-cyclodextrin tablets 
included organoleptic properties, size uniformity, hardness, disintegration time, friability, wetting 
time, water absorption ratio, in vitro dispersion time, atenolol content, and dissolution. 
 
Organoleptic properties  
  During the organoleptic evaluation, the smell, color, taste, and shape of the printed 
orodispersible atenolol tablets were observed (Allen and Ansel, 2014).  
 
Size uniformity 
The diameter and thickness of ten tablets were measured with a micrometer to determine the 
physical consistency of the produced tablets (Agoes, 2012).  
 
Hardness  
 Hardness is the amount of force needed to destroy a tablet during diameter testing. The 
orodispersible tablets were tested for hardness using a Monsanto Hardness Tester (Shahi et al., 
2013).  
 
Disintegration time 
 The disintegration time of the printed tablets was determined with a disintegration test 
apparatus (according to the United States Pharmacopeial Convention) using an aqua Purificata 
medium at a temperature of 37±0.5°C. This test used six samples of these tablets (Desai et al., 
2014).  
 
Friability 
  A tablet sample of 6.5 gram was placed in the friability test equipment, which was operated at 
a speed of 25 rpm for 4 minutes. The difference between the weights of the tablet before and after 
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the test was determined (Chandrasekhar et al., 2013). The friability (%) of the tablet was 
calculated using the following equation: 
 
                                        
                          
             
 x 100% 
 
Wetting time and water absorption ratio  
A filter paper with a diameter of 8 cm was placed in a 9cm petri dish. Then, the tablet was 
carefully placed on top of the filter paper. A total of 10 ml of soluble dye was poured into it. The 
time needed for the dye to reach the top surface of the tablet was recorded as the wetting time, 
and the mass of water absorbed by the tablet was the water absorption ratio (Kabra et al., 2011). 
 
In vitro dispersion time  
 The dispersion time of the tablets was evaluated in vitro using artificial saliva (phosphate 
buffer pH 6.8). Each tablet was placed in a container filled with 6 ml of phosphate buffer pH 6.8 
at a temperature of 37±0.5ºC. The time it required to disintegrate was recorded as the in vitro 
dispersion time (Kumare et al., 2013). 
 
Content analysis 
The content of the tablet was identified with Ultra Performance Liquid Chromatography 
(UPLC). Ten tablets were crushed and weighed, and ± 400.0 mg of the substance (equivalent to 
50 mg of atenolol powder) was put into a 100 ml volumetric flask, added with 50 ml of the 
mobile phase, and subjected to ultrasonic analysis for 5 minutes. The mobile phase was added 
until the etched line on the flask. One ml of the solution was removed to a 25ml volumetric flask 
using a pipette and diluted with the mobile phase until it reached the graduation line. The area of 
this solution sample was observed with a ULPC instrument, and the atenolol levels in the 
orodispersible tablets were measured (Departemen Kesehatan Republik Indonesia, 2014). 
 
Dissolution test 
The dissolution test of the orodispersible atenolol tablets was carried out according to the 
procedure described in the Farmakope Indonesia V (Departemen Kesehatan Republik Indonesia, 
2014). This test used a type-2 apparatus (paddle) at a speed of 50 rpm for 60 minutes. Ten ml of 
the samples were extracted after 1, 3, 5, 15, 30, 45, and 60 minutes. Each solution from these 
sampling times was tested to determine their dissolved atenolol content using Ultra Performance 
Liquid Chromatography (UPLC).    
 
Stability test 
 The orodispersible atenolol-β-cyclodextrin (1:1) tablets were subjected to an accelerated 
stability test for two weeks. The analyzed tablets were stored at 40±2 
0
C/RH 75±5 % and checked 
after two weeks. The observed parameters included wetting time, in vitro dispersion, water 
absorption ratio, dissolution, and the level of the active ingredient atenolol. 
  
DATA ANALYSIS 
  The characteristics of the atenolol-β-cyclodextrin (1:1) inclusion complex and the data 
obtained from the pre- and post-compression evaluations of atenolol-β-cyclodextrin (1:1) powder 
were analyzed descriptively. The results of the stability test of the orodispersible atenolol-β-
cyclodextrin (1:1) tablets, which included the wetting time, in vitro dispersion, water absorption 
ratio, dissolution, and the level of the active ingredient atenolol, from Day 0 to Day 14 were 
analyzed statistically using a paired t-test.  
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RESULTS AND DISCUSSION 
 The atenolol-β-cyclodextrin inclusion complex (1:1) was prepared using the solvent 
evaporation method. Several methods were used to characterize the resulted inclusion complex. 
This characterization is one technique to predict interactions and complex formation between 
drug molecules and β-cyclodextrin. The identified characteristics of the atenolol-β-cyclodextrin 
(1:1) inclusion complex with Fourier-transformed Infrared (FT-IR) are depicted in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The visualization of the infrared spectra of (A) atenolol, (B) β-cyclodextrin, and (C) 
atenolol-β-cyclodextrin (1:1) inclusion complex 
 
In this image, atenolol shows specific characteristics at wavenumbers 3355.53 cm
-1
, 
3178.11 cm
-1
 (-CO-NH), 1637.27 cm
-1
 (-C=O, NH Primer), 1515.78 cm
-1
 (-N-C=O, NH 
Secondary), 1418.39 cm
-1
 (H2N-CO-). Meanwhile, β-cyclodextrin shows specific characteristics 
at 3367.1 cm
-1
 (OH stretching, broad), 1415.49 cm
-1
 (O-H bending, α-CH2 bending, CH2 
deformation), and 1336.43 cm
-1
 (O-H bending). The infrared spectrum or band of the atenolol-β-
cyclodextrin inclusion complex (1:1) widens at 3355.53 cm
-1
. The widening of the peak is similar 
to the character of the infrared spectrum of β-cyclodextrin. The transmittance peak at 3178.11 cm-
1
 does not appear in the infrared spectrum of the inclusion complex. These results suggest that an 
interaction between the functional groups of the drug molecules and the groups located in the β-
cyclodextrin cavity has occurred through hydrogen bonding (Gite, 2014). In the atenolol inclusion 
complex, the new peak at 3724.87 cm
-1
 replaces the old peak of pure atenolol, i.e., at 1613.16 cm
-
1
. This condition suggests the loss of the –CO-NH- group in the inclusion complex (Gite, 2014). 
Based on the characterization of the crystallographic aspects, atenolol has sharp peaks with 
high intensity, meaning that pure atenolol has high crystallinity (Buha et al., 2012). Meanwhile, 
β-cyclodextrin has lower intensity than atenolol. From the diffractogram of the atenolol-β-
cyclodextrin inclusion complex, a shift in the peak position and a decrease in the specific peak 
height of atenolol (compared to pure atenolol) are apparent. Such a decrease represents that the 
inclusion complex has lower crystallinity (Ghosh et al., 2011). The diffractograms of atenolol, β-
cyclodextrin, and atenolol-β-cyclodextrin inclusion complex are presented in Figure 2.  
A 
B 
C 
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Figure 2. The characterization of (A) atenolol, (B) β-cyclodextrin, and (C) atenolol-β-cyclodextrin 
(1:1) inclusion complex using X-ray diffraction 
 
Scanning electron microscopy was used to observe the surface morphology of the powders 
of atenolol, β-cyclodextrin, and inclusion complexes. Morphology is the shape and size of 
constituent particles of a formed system. The results of the surface morphology analysis showed 
that atenolol was shaped irregularly like chunks, while the β-cyclodextrin molecule had an 
elongated cube shape. Also, the surface morphology of the atenolol-β-cyclodextrin inclusion 
complex showed that the atenolol molecule was attached to the surface of β-cyclodextrin and 
covered by β-cyclodextrin. This condition implies that atenolol has been dispersed and adsorbed 
physically on the surface of β-cyclodextrin (Ghosh et al., 2011). The observation results of the 
morphology of atenolol, β-cyclodextrin, and the inclusion complex under a scanning electron 
microscope are presented in Figure 3. 
 
 
Figure 3. The observation results of the surface morphology of (A) atenolol, (B) β-
cyclodextrin, and (C) the atenolol-β-cyclodextrin inclusion complex under a 
scanning electron microscope at 5000x magnification 
 
The thermal characteristics of atenolol, β-cyclodextrin, and the atenolol-β-cyclodextrin 
inclusion complex were observed with differential scanning calorimetry (DSC). The DSC 
thermograms of these three test subjects are presented in Figure 4. 
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Figure 4. The thermograms of (A) atenolol, (B) β-cyclodextrin, and (C) the atenolol-β-cyclodextrin 
(1:1) inclusion complex resulted from differential scanning calorimetry 
 
The DSC thermogram of atenolol shows an endothermic peak at 153.89ºC, which 
coincides with the melting point of atenolol, while that of β-cyclodextrin has a wide endothermic 
peak at around 100ºC, signifying the release of water molecules from its structure (Gite, 2014). 
As for the atenolol-β-cyclodextrin inclusion complex, a shift in the melting point (endothermic 
peak) of atenolol to 83.70°C is visible in the thermogram. This change means that the 
combination of atenolol and β-cyclodextrin has created a mixture of inclusion complex. The 
inclusion complex appears to have more than one endothermic peak that may be due to the 
dehydration from β-cyclodextrin in the range 70-110°C (Hadaruga et al., 2008). 
The characterization of the atenolol-β-cyclodextrin inclusion complex using the infrared 
spectrum and differential scanning calorimetry confirmed the interactions between atenolol and β-
cyclodextrin. Hydrogen bonds are formed between the -CO-NH2 and–NH groups from the 
atenolol molecule with the –OH group in β-cyclodextrin. As observed under a scanning electron, 
the morphology of the atenolol-β-cyclodextrin inclusion complex affirms the existence of this 
interaction. This finding suggests that atenolol is dispersed in the β-cyclodextrin cavity in the 
form of fine particles and attaches to the surface of β-cyclodextrin. Overall, based on the results 
of the characterization, the atenolol-β-cyclodextrin inclusion complex has been formed.  
Aside from atenolol-β-cyclodextrin inclusion complex, the characterization was 
performed on the co-processed crospovidone-croscarmellose sodium. It analyzed any changes in 
functional groups using an infrared spectrum and in crystallographic aspects using X-ray 
diffraction. The infrared spectra of crospovidone, croscarmellose sodium, and co-processed 
crospovidone-croscarmellose sodium are visualized in Figure 5. 
C 
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Figure 5. The visualization of the infrared spectra of (A) crospovidone, (B) croscarmellose 
sodium, and (C) co-processed crospovidone-croscarmellose sodium 
 
The graph shows that crospovidone has specific absorbances at wavenumbers 1653.66 
cm
-1
 (C=O), 1494.56 cm
-1
, 1462.74 cm
-1
, and 1423.21 cm
-1
 (pyrrolidone group). Meanwhile, the 
specific absorbance of croscarmellose sodium is apparent at 3418.21 cm
-1
 (O-H), 2923.56 cm
-1
 
(C-H), 1077.05 cm
-1
 (C-O ester), and 895.773 cm
-1
 (C-O-C). The observation on the functional 
groups in the co-processed crospovidone-croscarmellose sodium revealed a shift in the specific 
absorbance of crospovidone and croscarmellose sodium. The crystallographic analysis results of 
the co-processed crospovidone-croscarmellose sodium with X-ray diffraction are presented in 
Figure 6. 
 
 
Figure 6. The visualization of the infrared spectra of (A) crospovidone, (B) croscarmellose sodium, 
and (C) co-processed crospovidone-croscarmellose sodium 
 
Based on the results of the crystallographic analysis, the height difference of the peak of 
the co-processed superdisintegrants indicates an interaction between croscarmellose sodium and 
crospovidone after co-processing. After comparing the wet weight to the dry weight of the co-
processed crospovidone-croscarmellose sodium powder, this study found that the moisture 
content of this powder met the pharmaceutical requirements, i.e., 2.39%.  
The atenolol-β-cyclodextrin inclusion complex was formulated into orodispersible tablets. 
The created powder mixture was subjected to pre-compression analysis, including flow 
characteristics, compressibility index, Hausner ratio, and moisture content. When poured through 
the funnel, the powder flowed at a speed of 7.44 g/s, classifying it as flowable (Hahm and 
A 
B 
C 
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Augsburger, 2008). This procedure created a conical pile of granular matters on the horizontal 
plane with an angle of repose of 31.24º, and the powder mixture is thereby concluded as good 
(31-35º) (United States Pharmacopeial Convention, 2017). Compressibility index and Hausner 
ratio were also used to predict the flow characteristics and the capacity of the powder mixture to 
form tablets (Augsburger and Hoag, 2008). The compressibility index of the powder mixture was 
12.62%, meaning that this powder is compressible and qualified for the compression process 
(Agoes, 2012; Callahan et al., 1982). Another parameter that also determines the flow properties 
of the powder is moisture content (Crouter and Briens, 2013). Previous research has shown that 
the ideal moisture content for printing tablets with cellulose microcrystalline fillers is in the range 
of 3-5% (Sun, 2008). The moisture content of the orodispersible atenolol-β-cyclodextrin tablets 
with co-processed crospovidone-croscarmellose sodium and Poloxamer 188 in this study was 
3.26%. 
Because the pre-compression evaluation showed that the atenolol-β-cyclodextrin powder 
met the requirements for tableting, it was printed into tablet dosage forms using a compression 
machine. The orodispersible atenolol-β-cyclodextrin tablets with co-processed crospovidone-
croscarmellose sodium and Poloxamer 188 were subjected to post-compression evaluation. The 
organoleptic characteristics of these tablets are white, round in shape, mint odor, and sweet taste. 
The physical appearance of the tablet can be seen in Figure 7. 
 
 
 
Figure 7. The physical appearance of the orodispersible atenolol-β-cyclodextrin tablet with co-
processed crospovidone-croscarmellose sodium and Poloxamer 188 
 
The results of the post-compression evaluation are summarized in Table II. Based on the 
uniformity test, no size variation was found in the printed orodispersible tablets, signifying the 
absence of problems with the flow of the powder mixture during the tableting process. Another 
parameter that must be considered in the tablet formulation is hardness (Shahi et al., 2013). The 
hardness of the produced tablets meets the required hardness of non-coated tablets (4-8 kg). Other 
evaluations related to their mechanical characteristics are friability and abrasion (Nagar et al., 
2011). The friability and abrasion test results are in line with the predefined standards for tablets 
with good mechanical resistance, i.e., <1% (United States Pharmacopeial Convention, 2017). 
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Table II. The results of the post-compression evaluation on the printed orodispersible 
atenolol-β-cyclodextrin tablets with co-processed crospovidone-
croscarmellose sodium and Poloxamer 188 (The figures are the average 
value of three replications ± SD) 
 
Parameters Specification Mean ± SD 
Organoleptic 
properties 
Color White White 
Smell Mint Mint 
Taste Mint and sweet Mint and sweet 
Shape Round Round 
Tablet hardness (kg) 2-4 kg 6.6 ± 0.7 
Size uniformity Thickness 4.00 mm 4.125 ± 0.14 
Diameter 11.00 mm 11.00 ± 0.00 
Disintegration time (s) <1 minute 36.67 ± 1.21  
In vitro dispersion time (s)  104.88 ± 0.42 
Friability (%) <1% 0.30% 
Abrasion (%) <1% 0.16% 
Wetting time (detik) <3 minutes 96.81 ± 1.09 
Water absorption ratio  4.92% ± 0.07 
Active ingredient level (%) 90-110 % 98.11% ± 0.21 
Dissolution 85% 84.39% ± 3.34 
 
Wetting time and water absorption ratio illustrate the porosity and water-attracting capacity 
of the structure of the orodispersible atenolol-β-cyclodextrin tablets. In the wetting time 
evaluation, the entire surface of the tablet was wetted rapidly in 96.81±1.09 s because the co-
processed superdisintegrants, i.e., crospovidone-croscarmellose sodium, worked synergistically 
by attracting water and through capillary action (Desai et al., 2016). The calculated water 
absorption ratio of the tablet was 4.92% ± 0.07, meaning that the tablet absorbs water mainly 
through the mechanism of wicking (Al-Ghabban et al., 2013).  
The wetting time has been shown to have a strong correlation with disintegration time and 
in vitro dispersion time (Al-Ghabban et al., 2013). It represents the initial stage that determines 
the disintegration time of tablets (Shankarrao et al., 2010). According to the U.S. FDA, good 
orodispersible tablets disintegrate in <1 minute (FDA, 2008). The orodispersible atenolol-β-
cyclodextrin tablets produced in this study disintegrated in 36.67 ± 1.21 s, which is within the 
preferred disintegration time listed in the drug compendia. The in vitro dispersion evaluation 
aimed to predict the characteristics of the tablet dispersion when exposed to saliva in the oral 
cavity (Kaur et al., 2014). The results showed that the in vitro dispersion time ranged from 90 to 
110 s, indicating that the tablet is rapidly destroyed when placed in the oral cavity. The 
orodispersible atenolol-β-cyclodextrin tablets with co-processed crospovidone-croscarmellose 
sodium and Poloxamer 188 contained 98.11 ± 0.21 % of the active ingredient atenolol. At this 
concentration, they have met the required level of atenolol in a tablet dosage form according to 
the Farmakope Indonesia Edition V, namely 90%-110% (Departemen Kesehatan Republik 
Indonesia, 2014). Other parameters to determine the efficacy of the dosage form are dissolution 
process and the amount of dissolved drug in a certain period (%Q) in a dissolution medium. The 
amount of dissolved atenolol in the orodispersible atenolol-β-cyclodextrin tablets in this research 
was 84.39 ± 3.34 %, which was dissolved in 30 minutes. Although these results have not met the 
requirements set in the Farmakope Indonesia V (%Q 85%), the dissolution of atenolol is 1.4 times 
higher than the results of a previous study that did not use Poloxamer 188 (surfactant). The 
dissolution profiles of the orodispersible atenolol-β-cyclodextrin tablets with co-processed 
Pharmaciana ISSN: 2088 4559; e-ISSN: 2477 0256  
Formulasi  tablet  orodispersibel … (Rani et al.,) 
 
 
 
 
295 
crospovidone-croscarmellose sodium and Poloxamer 188 can be seen in Figure 8. The addition of 
Poloxamer 188 has been shown to reduce the interfacial tension between atenolol and the 
dissolution medium, but the optimal concentration of Poloxamer 188 in orodispersible atenolol-b-
cyclodextrin tablets needs to be investigated further. 
  
 
 
Figure 8. The dissolution profile of orodispersible atenolol-β-cyclodextrin tablets with co-processed 
crospovidone-croscarmellose sodium and Poloxamer 188  
 
In this study, the orodispersible atenolol-β-cyclodextrin tablets were subjected to an 
accelerated stability test for two weeks. They were stored in a climatic chamber at a temperature 
of 40º ± 2º C and RH 75 ± 5%. This test attempted to determine the resistance of the tablet within 
the predefined specifications during storage and use to ensure product quality (Türkoǧlu et al., 
2004). The paired t-test with α= 0.05 confirmed that the characteristics of the tablets, as seen from 
the wetting time, water absorption ratio, in vitro dispersion time, atenolol content, and dissolution, 
did not show any significant differences. This finding denotes that the orodispersible atenolol-β-
cyclodextrin tablets formulated with co-processed crospovidone-croscarmellose sodium and 
Poloxamer 188 are stable in two-week storage at 40º±2ºC dan RH 75±5 %. 
 
CONCLUSION    
The atenolol-β-cyclodextrin inclusion complex prepared using the solvent evaporation 
method can be developed into an orodispersible tablet after direct compression. The addition of 
co-processed crospovidone-croscarmellose sodium into the formulation of orodispersible 
atenolol-β-cyclodextrin tablets can accelerate tablet disintegration and, therefore, dissolution can 
occur faster. The addition of Poloxamer 188 has been proven to increase the dissolution of 
atenolol from orodispersible tablets by 1.4 times than previous studies, but it has not met the 
requirements set in the Farmakope Indonesia, that is, 85% of atenolol dissolved within 30 
minutes. Further research to determine the optimal concentration of Poloxamer 188 to improve 
atenolol dissolution is recommended. 
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